22:05 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Lupus Mouse studies suggest inhibiting CTSS could help treat lupus. In a mouse model of the disease, CTSS levels were higher in dendritic cells from the spleen, blood and bone marrow than from the...
07:00 , Oct 8, 2015 |  BC Innovations  |  Product R&D

Medicines Co.'s double play

While inhibiting β-lactamases is one of the dominant strategies for combating antibiotic resistance, companies have only had success targeting one of the two classes of the enzyme, serine β-lactamases, and have made little progress against...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

Amura, Gruenenthal deal

Gruenenthal and Amura's Amura Therapeutics Ltd. subsidiary partnered to develop Amura's cathepsin inhibitors to treat pain and inflammation. Gruenenthal will retain worldwide rights to develop and commercialize products arising from the deal. Amura received an...
07:00 , Sep 24, 2007 |  BC Week In Review  |  Clinical News

Amura preclinical data

In primates, Amura's oral cathepsin K inhibitors reduced C-terminal and N-terminal crosslinked telopeptides of Type I collagen , which are 2 biomarkers of bone absorption. The compounds were well tolerated. Amura Holdings Ltd. , Babraham,...
08:00 , Feb 26, 2007 |  BC Week In Review  |  Company News

Amura deal

Amura spun out Prosarix Ltd. (Cambridge, U.K.) to commercialize the ProtoDiscovery computational screening and design technology that Amura acquired when it merged with Proteom Ltd. last year (see BioCentury, May 22, 2006). Financial terms were...
07:00 , Jun 12, 2006 |  BioCentury  |  Strategy

Engineering its engine

By choosing to merge, Amura Ltd. has broadened its capabilities beyond the protease space originally targeted by its small molecule medicinal chemistry platform, while Proteom Ltd. and its in silico screening and drug design technology...
07:00 , May 22, 2006 |  BC Week In Review  |  Company News

Amura Ltd., Proteom deal

The companies merged to form Amura Holdings Ltd. The deal combines Proteom's ProtoDiscovery computational screening and design technology with Amura's AMcore bicyclic molecular scaffold chemistry. Amura Ltd. , Cambridge, U.K.   Proteom Ltd. , Cambridge,...